Antibiotic Stewardship 2026: Resistance Trends and Empiric Therapy Updates

The Resistance Crisis: 2026 Epidemiology

Antimicrobial resistance (AMR) accounts for an estimated 1.27 million deaths annually worldwide and contributes to 4.95 million deaths. In the United States, carbapenem-resistant Enterobacterales (CRE), extended-spectrum beta-lactamase (ESBL) producers, and methicillin-resistant Staphylococcus aureus (MRSA) remain the most clinically significant resistant organisms.

Empiric Therapy Updates: What Changed

Updated IDSA guidelines recommend ceftriaxone plus metronidazole (instead of fluoroquinolones) for complicated intra-abdominal infections. For community-acquired pneumonia requiring hospitalization, the combination of beta-lactam plus macrolide remains first-line, with respiratory fluoroquinolone monotherapy reserved as an alternative. Empiric MRSA coverage should be considered when local MRSA prevalence exceeds 20% or in patients with prior MRSA history.

Rapid Diagnostics: Changing the Paradigm

Rapid molecular diagnostic platforms (BioFire FilmArray, Accelerate Pheno, T2Biosystems) provide pathogen identification and resistance gene detection within 1-6 hours, compared to 48-72 hours for conventional culture and susceptibility. Studies demonstrate that coupling rapid diagnostics with antimicrobial stewardship programs reduces time to appropriate therapy by 12-24 hours and decreases mortality in bacteremia.